SPDR S&P Pharmaceuticals ETF
XPH
XPH
58 hedge funds and large institutions have $117M invested in SPDR S&P Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
93% less call options, than puts
Call options by funds: $86K | Put options by funds: $1.32M
Holders
58
Holding in Top 10
–
Calls
$86K
Puts
$1.32M
Top Buyers
| 1 | +$53.3M | |
| 2 | +$1M | |
| 3 | +$887K | |
| 4 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
+$557K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$523K |
Top Sellers
| 1 | -$8.15M | |
| 2 | -$5.49M | |
| 3 | -$4.86M | |
| 4 |
LWM
Lionsbridge Wealth Management
Jacksonville Beach,
Florida
|
-$1.49M |
| 5 |
GSIAS
Garden State Investment Advisory Services
Red Bank,
New Jersey
|
-$732K |